Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $8 price target The company is developing chronic steroid treatments for rare diseases with “blockbuster potential,” the analyst tells investors in a research note. The firm believes the company’s EryDex is set to become a blockbuster treatment in the lead ataxia-telangiectasia indication alone.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX: